SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy. [PDF]
Front Immunol, 2023 BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short ...
Cini JK +8 more
europepmc +5 more sources
SON-1010: an albumin-binding IL-12 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy. [PDF]
Front ImmunolBackgroundCytokines have been promising cancer immunotherapeutics for decades, yet only two are licensed to date. Interleukin-12 (IL-12) is a potent regulator of cell-mediated immunity that activates NK cells and interferon-γ (IFNγ) production.
Cini JK +9 more
europepmc +5 more sources
A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers [PDF]
Frontiers in ImmunologyBackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 study
Richard T. Kenney +10 more
doaj +5 more sources
Bordetella pertussis and Bordetella bronchiseptica filamentous hemagglutinins are processed at different sites. [PDF]
FEBS Open Bio, 2018 Filamentous hemagglutinins (FHA) of Bordetellae are produced by processing of the ~ 130‐kDa C‐terminal prodomains of their FhaB precursors by the subtilisin‐like protease SphB1. Despite near‐complete sequence conservation of the processed FhaB segments, the SphB1 cleavage sites of FhaB from B. pertussis and B.
Jurnecka D, Man P, Sebo P, Bumba L.
europepmc +2 more sources
DataSheet_1_SON-1210 - a novel bifunctional IL-12 / IL-15 fusion protein that improves cytokine half-life, targets tumors, and enhances therapeutic efficacy.pdf [PDF]
, 2023 BackgroundThe potential synergy between interleukin-12 (IL-12) and IL-15 holds promise for more effective solid tumor immunotherapy. Nevertheless, previous clinical trials involving therapeutic cytokines have encountered obstacles such as short ...
Darrel J. Rezac (17677887) +8 more
core +1 more source
DataSheet_1_A phase I trial of SON-1010, a tumor-targeted, interleukin-12-linked, albumin-binding cytokine, shows favorable pharmacokinetics, pharmacodynamics, and safety in healthy volunteers.pdf [PDF]
BackgroundThe benefits of recombinant interleukin-12 (rIL-12) as a multifunctional cytokine and potential immunotherapy for cancer have been sought for decades based on its efficacy in multiple mouse models. Unexpected toxicity in the first phase 2 study
Richard T. Kenney (15289313) +9 more
core +1 more source
The Recruitment and Activation of Plasminogen by Bacteria-The Involvement in Chronic Infection Development. [PDF]
Int J Mol Sci, 2023 Satala D +4 more
europepmc +1 more source
Protective Efficacy of Anti-Hyr1p Monoclonal Antibody against Systemic Candidiasis Due to Multi-Drug-Resistant <i>Candida auris</i>. [PDF]
J Fungi (Basel), 2023 Singh S +5 more
europepmc +1 more source
Serum proteases prevent bacterial biofilm formation: role of kallikrein and plasmin. [PDF]
Virulence, 2021 Arenas J +6 more
europepmc +1 more source
Gram-Negative Bacteria Holding Together in a Biofilm: The Acinetobacter baumannii Way. [PDF]
Microorganisms, 2021 Pompilio A +5 more
europepmc +1 more source